Search research articles
Contact Us
Filters
Showing results (211-220 of 303) with videos related to
Page
of 31
Sort By:
British Journal of Cancer
|
January 31, 2018
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)
Jong-Mu Sun, Ki Hyeong Lee, Bong-Seog Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2019
The First-week Proliferative Response of Peripheral Blood PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, et al.
BMC Ophthalmology
|
January 11, 2020
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors
Eunhae Shin, Dong Hui Lim, Jisang Han, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 7, 2023
Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC
Tae Hee Hong, Yeong Hak Bang, Cheol Yong Joe, et al.
Translational Lung Cancer Research
|
March 18, 2024
Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses
Sehhoon Park, Jun-Kyu Kang, Naeun Lee, et al.
Future Oncology (London, England)
|
February 9, 2019
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Ken Kato, Manish A Shah, Peter Enzinger, et al.
Cancer Chemotherapy and Pharmacology
|
March 26, 2014
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
Ji Yun Lee, Sung Hee Lim, Moonjin Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 14, 2019
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
Youjin Kim, Chu Hyun Kim, Ho Yun Lee, et al.
Molecular Cancer Research : MCR
|
June 17, 2010
Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptor
Hae Hyun Jung, Yeon Hee Park, Hyun Jung Jun, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 3, 2019
Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery
Won Kyung Cho, Dongryul Oh, Hong Kwan Kim, et al.
Page
of 31
Search research articles
Search
Showing results (211-220 of 303) with videos related to
Sort By:
Page
of 31
British Journal of Cancer
|
January 31, 2018
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)
Jong-Mu Sun, Ki Hyeong Lee, Bong-Seog Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2019
The First-week Proliferative Response of Peripheral Blood PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, et al.
BMC Ophthalmology
|
January 11, 2020
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors
Eunhae Shin, Dong Hui Lim, Jisang Han, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 7, 2023
Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC
Tae Hee Hong, Yeong Hak Bang, Cheol Yong Joe, et al.
Translational Lung Cancer Research
|
March 18, 2024
Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses
Sehhoon Park, Jun-Kyu Kang, Naeun Lee, et al.
Future Oncology (London, England)
|
February 9, 2019
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Ken Kato, Manish A Shah, Peter Enzinger, et al.
Cancer Chemotherapy and Pharmacology
|
March 26, 2014
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
Ji Yun Lee, Sung Hee Lim, Moonjin Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 14, 2019
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
Youjin Kim, Chu Hyun Kim, Ho Yun Lee, et al.
Molecular Cancer Research : MCR
|
June 17, 2010
Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptor
Hae Hyun Jung, Yeon Hee Park, Hyun Jung Jun, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 3, 2019
Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery
Won Kyung Cho, Dongryul Oh, Hong Kwan Kim, et al.
Page
of 31